SLC22A14: A Characterized Protein with Unique Localization and Function

Target Name: SLC22A14

NCBI ID: G9389

SLC22A14

SLC22A14: A Characterized Protein with Unique Localization and Function

SLC22A14 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the Sodium Chloride Transporter (SLC) family, which is a family of proteins that transport chloride ions across cell membranes . SLC22A14 is specifically characterized by its unique structure, which consists of a long amino acid sequence that is responsible for its unique localization and function.

One of the key features of SLC22A14 is its unique localization to the endoplasmic reticulum (ER). The ER is a membrane-bound organelle that plays a critical role in the regulation of intracellular signaling pathways and is responsible for the final sorting of proteins to their respective localizations in the cell. SLC22A14 is able to localize to the ER due to its unique transmembrane domain, which consists of a long amino acid sequence that is involved in the formation of a transmembrane region.

In addition to its unique localization to the ER, SLC22A14 is also characterized by its involvement in various cellular processes. For example, SLC22A14 has been shown to play a role in the regulation of ion channels, which are responsible for the flow of charged particles through the cell membrane. Additionally, SLC22A14 has been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway and the Wnt pathway.

SLC22A14 has also been shown to be a potential drug target. The TGF-β pathway is a critical pathway that is involved in the regulation of cell growth, differentiation, and survival, and is a target for a variety of therapeutic drugs. SLC22A14 has been shown to play a role in the regulation of TGF-β signaling, and therefore, it may be a useful target for the development of therapeutic drugs.

In addition to its potential as a drug target, SLC22A14 has also been shown to be a potential biomarker. The regulation of SLC22A14 has been shown to be involved in various cellular processes, including the regulation of cell growth, differentiation, and survival. Therefore, changes in the level of SLC22A14 may be indicative of certain diseases, such as cancer. Therefore, SLC22A14 may be a useful biomarker for the diagnosis and monitoring of various diseases.

In conclusion, SLC22A14 is a protein that is characterized by its unique localization to the ER and its involvement in various cellular processes. Its unique structure and function make it a potential drug target, and its involvement in the regulation of TGF-β signaling makes it a potential biomarker for the diagnosis and monitoring of various diseases. Further research is needed to fully understand the role of SLC22A14 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 22 Member 14

Functions: Riboflavin transporter localized at the inner mitochondrial membrane of the spermatozoa midpiece, which is required for male fertility (By similarity). SLC22A14-mediated riboflavin transport is essential for spermatozoa energy generation and motility: riboflavin is the precursor of FMN and FAD, which are coenzymes of many enzymes in the TCA cycle (the citric acid cycle) in mitochondria (By similarity). Required for sperm motility and normal sperm flagellar structure (By similarity)

The "SLC22A14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets